CANSINOBIO (06185) released its performance report for 2024, with a net loss attributable to shareholders of 379 million yuan, narrowing by 74.45% year-on-year.

CANSINOBIO(06185) released its 2024 annual performance report, with total operating income of 846 million yuan, a year-on-year increase of 137.01%; net loss attributable to owners of the parent company was 379 million yuan, a year-on-year decrease of 74.45%; basic loss per share was 1.53 yuan. During the reporting period, total operating income increased by 137.01% year-on-year, mainly due to: as the only quadrivalent meningococcal conjugate vaccine on the Chinese market, MCV4, the Group continued to increase sales by accurately positioning its market and improving product penetration rate, achieving rapid sales growth; at the same time, the impact of global public health events on the Group's operations has been largely eliminated. Therefore, the Group's operating income has significantly increased compared to the same period last year.